Background Carbapenems are widely used for the management of bloodstream infections
(BSIs) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL …

Abstract Objectives Bloodstream infections (BSIs) caused by extended-spectrum beta-
lactamase-producing Enterobacteriaceae (ESBL-PE) have become a worldwide public …

Background Infections due to extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae pose a major public health threat due to poor outcomes and high …

Background There is little information about the efficacy of active alternative drugs to
carbapenems except β-lactam/β-lactamase inhibitors for the treatment of bloodstream …

The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae
(ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems …

Objective: To present systematic recommendations for carbapenem-sparing therapy against
extended-spectrum β-lactamases (ESBLs) Enterobacteriaceae bloodstream infections …

Abstract (See the Editorial Commentary by Perez and Bonomo, on pages 175–7.)
Background. Extended-spectrum ß-lactamase–producing Escherichia coli (ESBL-EC) is an …

The efficacy of empirical non-carbapenem antibiotics for extended-spectrum beta-lactamase-
producing Enterobacteriaceae bacteremia (ESBL-B) is still inconclusive. We conducted a …

Background Extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae are
often susceptible in vitro to β-lactam/β-lactamase inhibitor (BLBLI) combination antibiotics …

Objectives To study the comparative mortality associated with carbapenems and alternative
antibiotics for the treatment of patients with extended-spectrum β-lactamase (ESBL)-positive …